drugset / Trial / NCT01147848

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

NCT01147848

Phase 3 Completed 810 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.

Timeline

Start
2010-06
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 100 ug Oral
Comparator Fluticasone propionate Other / unclassified 250 ug Oral
Comparator Salmeterol Other / unclassified 50 ug Oral
Subject Vilanterol Other / unclassified 25 ug Oral

Indications